Faeth Therapeutics stock analysis: a pre-revenue clinical biotech trading near its two-year high, with no debt, steep losses and a model rating of N/A.
@2026 – All Right Reserved.
Category:
Health Care
-
-
BiotechnologyUS Stocks
Madrigal’s Revenue Is Up 71% as Rezdiffra Ramps – the Stock Is Already Near Its Highs
Madrigal Pharmaceuticals stock analysis: 71% revenue growth meets a rich 24x price-to-book near two-year highs. Model signal: Hold.
-
BiotechnologyUS Stocks
IDEAYA Biosciences: Trading Near a Two-Year High While the Model Flags a Sell
IDEAYA Biosciences, Inc. stock analysis: shares sit near a two-year high while a -36.4% gross margin and 25/100 quality score drive a Sell signal.
-
Insmed Incorporated stock analysis: revenue up 296.1% with a 90/100 growth score, offset by a -76.9% net margin and a Hold signal from our model.
-
BiotechnologyUS Stocks
ACADIA Pharmaceuticals Stock Hits a 2-Year High as the Biotech Turns Consistently Profitable
ACADIA Pharmaceuticals stock analysis: ACAD hits a 2-year high on strong profitability, but a rich EV/EBITDA multiple keeps the model at Hold.
-
Beam Therapeutics stock analysis: BEAM nears its 2-year high as revenue drops 94% YoY, driving the model’s signal to Sell.
-
BiotechnologyUS Stocks
Recursion Pharmaceuticals Stock Slides Near Its Two-Year Low as Revenue Reverses
Recursion Pharmaceuticals stock analysis: RXRX nears its two-year low as revenue drops 60.1% TTM and cash burn continues despite a strong balance sheet.
Newer Posts